IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Endocare, Inc.
(Nasdaq: ENDO), an innovative medical device company focused on the
development of minimally invasive technologies used by urologists and
interventional radiologists for tissue and tumor ablation, announced today
that physicians from leading medical institutions including Mayo Clinic,
Memorial Sloan-Kettering Cancer Center and the University of Wisconsin School
of Medicine, among others, will present a total of 38 scientific papers,
posters and educational exhibits related to cryoablation and its effectiveness
for treating a wide variety of cancers this week at the 93rd Scientific
Assembly and annual meeting of the Radiological Society of North America
(RSNA) in Chicago. Cryoablation is a minimally invasive procedure in which
tumors are targeted with ultrasound, computed tomography or magnetic resonance
imaging guidance and treated by freezing.
The presentations include a 36-month update of a multi-center study that
demonstrates the safety, effectiveness and durability of cryoablation as a
means of dramatically reducing focal pain for patients whose cancer has spread
to their bones. The update on the study, which includes data from 50 of a
planned total of 60 patients, is being presented by Matthew Callstrom, M.D.,
PhD of Mayo Clinic, the lead investigator.
The conference also includes several presentations focused on percutaneous
renal, or kidney, cryoablation, the fastest growing cryoablation treatment.
Last January the Centers for Medicare and Medicaid Services issued for the
first time a payment code for percutaneous renal cryoablation, a procedure
that allows physicians to destroy small tumors in the kidney by inserting a
probe directly through the skin and freezing the cancerous tissue.
Data were also presented on the effectivPage: 1 2 3 4 Related biology technology :1
. Best Practices Document on Cryoablation Posted on Website of American Urological Association2
. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity3
. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment4
. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference5
. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting6
. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 20077
. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting8
. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH9
. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 200810
. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics11
. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008